Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

H. Bonnefoi, W. Jacot, M. Saghatchian, C. Moldovan, L. Venat-bouvet, K. Zaman, E. Matos, T. Petit, A. Bodmer, N. Quenel-tueux, C. Chakiba, P. Vuylsteke, G. Jerusalem, E. Brain, O. Tredan, C. G. M. Messina, L. Slaets, D. Cameron

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)325-332
JournalAnnals of Oncology
Issue number2
Publication statusPublished - 1 Feb 2015

Cite this